Küleon
Membership Level: Standard Community
Küleon develops small molecule therapeutics for neuropsychiatric conditions that can be modulated through serotonin receptors found in the prefrontal cortex of the brain. Selective modulation of certain serotonin receptor subtypes can be leveraged to treat a variety of diseases and disorders, including addiction (to alcohol, cocaine, nicotine, methamphetamines, and more), schizophrenia, obesity, pain, inflammation, and neurodegeneration. BioUtah welcomes CEO and entrepreneur, Allen Barbieri, and Küleon to Utah and the BioUtah community.
More